Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
AbCellera received a grant from the Bill & Melinda Gates Foundation to discover antibodies against Mycobacterium tuberculosis.
VANCOUVER, British Columbia, Jan. 19, 2017 -- AbCellera today announced a grant from the Bill & Melinda Gates Foundation to discover monoclonal antibodies against Mycobacterium tuberculosis (Mtb). The project will use AbCellera’s antibody discovery platform to generate panels of high-affinity monoclonal antibodies against 10 tuberculosis targets. These antibodies will be used for the development of new diagnostic tests for disease caused by Mtb. Dr. Carl Hansen, founding CEO of AbCellera commented: “It is a real honour to have the support of the Bill & Melinda Gates Foundation, and we are grateful for the chance to contribute in the fight against tuberculosis.”
Tuberculosis is one of the leading causes of death worldwide, with an estimated nine million new cases annually. Conventional diagnostic methods used in the developing world fail to identify individuals with disease caused by Mtb in more than half of all cases, and access to more sensitive tests that require specialized laboratory equipment is limited in many high-burden countries. The development of low-cost, point-of-care tests with greater specificity and sensitivity would have major impact on curtailing the spread of the disease in low- to middle-income countries that account for over 90% of tuberculosis cases.
AbCellera has established a microfluidic single-cell platform that enables the screening of millions of immune cells in a single day, greatly increasing the speed and efficiency of monoclonal antibody discovery from natural immune responses of immunized animals and human patients. AbCellera’s technology opens new avenues for human immune profiling and infectious disease research, with the potential to accelerate the development of urgently needed diagnostic tests and vaccines.
About AbCellera Biologics Inc.
AbCellera is a privately held company that provides enabling technologies to biotechnology and pharmaceutical partners to accelerate the discovery and development of next-generation monoclonal antibody therapies.
Contact Kevin Heyries Telephone: 604.827.4151 Email: [email protected] Web: www.abcellera.com
